HC Wainwright Reiterates Buy Rating for Emergent BioSolutions (NYSE:EBS)

Emergent BioSolutions (NYSE:EBS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 38.33% from the company’s current price.

EBS has been the topic of a number of other research reports. Benchmark increased their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. StockNews.com upgraded Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th.

Emergent BioSolutions Trading Up 6.1 %

Emergent BioSolutions stock opened at $10.84 on Tuesday. The stock has a 50-day moving average price of $9.25 and a 200 day moving average price of $9.26. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $15.10. The stock has a market cap of $587.53 million, a PE ratio of -2.64 and a beta of 1.60. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.88. The business had revenue of $293.80 million during the quarter, compared to the consensus estimate of $328.72 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same period in the previous year, the firm posted ($1.44) earnings per share. Equities research analysts predict that Emergent BioSolutions will post -0.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. purchased a new position in shares of Emergent BioSolutions in the 3rd quarter worth about $1,547,000. Oak Hill Advisors LP acquired a new position in Emergent BioSolutions during the third quarter valued at approximately $9,296,000. Assenagon Asset Management S.A. grew its stake in Emergent BioSolutions by 74.5% during the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after buying an additional 316,700 shares during the period. Geode Capital Management LLC increased its position in shares of Emergent BioSolutions by 4.6% in the third quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock worth $4,861,000 after acquiring an additional 25,776 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of Emergent BioSolutions in the 2nd quarter valued at $1,576,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.